Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors
Publication
, Conference
Erba, HP; Faderl, S; Claxton, DF; Arellano, M; Lyons, RM; Kovacsovics, TJ; Gabrilove, J; Eckert, S; Huebner, D; Kantarjian, HM
Published in: BLOOD
November 20, 2009
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 20, 2009
Volume
114
Issue
22
Start / End Page
822 / 823
Location
New Orleans, LA
Publisher
AMER SOC HEMATOLOGY
Conference Name
51st Annual Meeting and Exposition of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Faderl, S., Claxton, D. F., Arellano, M., Lyons, R. M., Kovacsovics, T. J., … Kantarjian, H. M. (2009). Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. In BLOOD (Vol. 114, pp. 822–823). New Orleans, LA: AMER SOC HEMATOLOGY.
Erba, Harry P., Stefan Faderl, David F. Claxton, M. Arellano, Roger M. Lyons, Tibor J. Kovacsovics, Janice Gabrilove, Stephen Eckert, Dirk Huebner, and Hagop M. Kantarjian. “Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.” In BLOOD, 114:822–23. AMER SOC HEMATOLOGY, 2009.
Erba HP, Faderl S, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, et al. Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. In: BLOOD. AMER SOC HEMATOLOGY; 2009. p. 822–3.
Erba, Harry P., et al. “Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.” BLOOD, vol. 114, no. 22, AMER SOC HEMATOLOGY, 2009, pp. 822–23.
Erba HP, Faderl S, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Huebner D, Kantarjian HM. Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. BLOOD. AMER SOC HEMATOLOGY; 2009. p. 822–823.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 20, 2009
Volume
114
Issue
22
Start / End Page
822 / 823
Location
New Orleans, LA
Publisher
AMER SOC HEMATOLOGY
Conference Name
51st Annual Meeting and Exposition of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology